Sunday , December 6 2020

Traders dump Zoom for Expedia as Pfizer vaccine teases life after COVID

TNW uses cookies to personalize content and ads to
make our site easier for you to use.
We do also share that information with third parties for
advertising & analytics.

Inside money, markets, and big tech

Zoom stock fell 21% as Expedia rallied 20%

Pfizer sent stock markets into a spin on Monday after the pharmaceutical giant shared promising results of its COVID-19 vaccine trials.

Traders, presumably buoyed by the idea of an eventual return to normal, dumped 2020’s most successful ‘stay-at-home‘ stocks for travel plays like Expedia (EXPE) and Booking Holdings (BKNG).

EXPE and BKNG jumped 20% and 16% respectively to bring them back into the green for the year-to-date.

[Read: Here’s what you need to know about Pfizer’s COVID-19 vaccine]

On the other hand, conference call darling Zoom Video (-21%) and digital signature prince DocuSign (-17%) collapsed, but remain significantly up in 2020.

US tech giants PayPal (PYPL), Netflix (NLX), and Amazon also fell, alongside gaming stocks Take-Two Interactive, Activision Blizzard, and NVIDIA.

The market’s sentiment also shows up at the macro-scale. The tech-heavy NASDAQ 100 index dropped more than 2% while the broader S&P 500 (which includes airline and old-school bank stocks) rose 1% to nearly break its September 2 record high.

Travel stocks EXPE and BKNG were indeed the NASDAQ 100’s biggest benefactors of Pfizer‘s glimpse into a post-COVID world, at least yesterday.

In fact, Norwolk-headquartered BKNG gained more dollar value than any other NASDAQ 100 company. Pfizer‘s announcement added $11.8 billion to BKNG’s market cap, which now sits close to $87 billion.

(If the visualizations below don’t show, try reloading this page in your browser’s “Desktop Mode”.)

Other big winners include coffee lord Starbucks ($5.8 billion increase), hotel kingpin Marriott International ($4.2 billion), and retail discounters Ross Stores ($4.6 billion).

As for the biggest market value losers: Beijing-headquartered saw more dollars drain from its market value than any other, down $102.2 billion (it’s still worth more than $1 trillion).

The four horsemen of our techpocalypse Amazon, Facebook, Microsoft, and Apple were next hardest hit, having collectively lost $215.2 billion from their market values yesterday.

Curiously, Pfizer‘s share price (PFE) didn’t pump quite as much as some ‘back-to-normal’ stocks.

Despite the company sourcing the (supposed) good news, PFE rose just 7.6% to break into the green again for 2020.

Still, PFE trails practically every relevant major index for the year-to-date. Pfizer has underperformed against the NASDAQ 100 and the S&P 500, as well as the more specific NASDAQ Biotechnology and S&P 500 Health indexes.

However morbid, it’s hard to say who needs Pfizer‘s vaccine more: the company itself, or the rest of the market that just placed huge bets on it actually working. Fingers crossed until we find out, I guess.

Published November 10, 2020 — 13:01 UTC

Thank you!

Copyright © 2006—2020.
All rights reserved.
Made with

This Article was first published on

About IT News Ug

Check Also

Tesla makes its S&P 500 debut in exactly 4.20 weeks

TNW uses cookies to personalize content and ads to make our site easier for you …

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.